ZYBAN

Compare ZYBAN  to:
Compare
Compare

Generic Name for ZYBAN

Bupropion HCl 150mg; sust-rel tabs.

Legal Classification:

Rx

Pharmacological Class for ZYBAN

Aminoketone.

Manufacturer of ZYBAN

GlaxoSmithKline Pharmaceuticals

Indications for ZYBAN

Aid in smoking cessation.

Adult dose for ZYBAN

Swallow whole. Set target quit date within 1–2 weeks after start. Treat for 7–12 weeks; reevaluate if no significant progress by week 7; up to 6 months' therapy has been shown to be effective. Avoid bedtime dosing. ≥18yrs: initially 150mg once daily for 3 days, then 150mg twice daily at least 8 hrs apart; max 300mg/day in divided doses. Severe hepatic cirrhosis: max 150mg every other day. Mild-moderate hepatic cirrhosis, renal impairment: may give less often.

Children's dosing for ZYBAN

<18yrs: not recommended.

Contraindications for ZYBAN

Seizure disorders. Bulimia. Anorexia nervosa. Within 14 days of MAOIs. Abrupt withdrawal of sedatives or alcohol. Other forms of bupropion (eg, Wellbutrin).

Precautions for ZYBAN

History or risk of seizures; discontinue if seizure occurs: do not restart. Hepatic or renal impairment (monitor closely). Depression: clinical worsening or suicidal risk (monitor). Bipolar disorder. Psychosis. Unstable heart disease. CHF. Recent MI. Hypertension. Elderly. Labor & delivery. Pregnancy (Cat.C): not recommended, attempt nondrug treatment first. Nursing mothers: not recommended.

Interactions for ZYBAN

See Contraindications. Avoid alcohol. May use with transdermal nicotine (monitor for hypertension). MAOIs, levodopa, amantadine may increase toxicity. Caution with drugs that lower seizure threshold (eg, quinolones, theophylline, antidiabetics, anorectics, CNS stimulants, systemic steroids, antidepressants, antipsychotics), or factors that lower seizure threshold (eg, opiate or cocaine addiction, excessive use of alcohol or sedatives). Caution with drugs metabolized by CYP2B6 (eg, orphenadrine, cyclophosphamide) or CYP2D6 including tricyclic antidepressants, SSRIs (eg, paroxetine, fluoxetine, sertraline), antipsychotics (eg, haloperidol, risperidone, thioridazine), β-blockers (eg, metoprolol), Class 1C antiarrhythmics (eg, propafenone, flecainide); consider dose reduction. May be affected by metabolic enzyme inducers (eg, carbamazepine, phenobarbital, phenytoin) or inhibitors (eg, cimetidine). Smoking cessation potentiates theophylline, warfarin, insulin, β-blockers, pentazocine, oxazepam, tricyclics (eg, imipramine), caffeine, acetaminophen, adrenergic antagonists (eg, prazosin, labetolol), others. Smoking cessation antagonizes adrenergic agonists (eg, isoproterenol, phenylephrine), others.

Adverse Reactions for ZYBAN

Dry mouth, insomnia, CNS or psychiatric effects (eg, dizziness, anxiety), rash (rarely may be serious, eg, erythema multiforme, Stevens-Johnson syndrome), pruritus, constipation, asthenia, fever, headache, palpitations, sweating, visual changes, anorexia, GI effects, urinary frequency.

How is ZYBAN supplied?

Tabs—60
Advantage Pack (1x60 tabs)—1

Related Disease:

Smoking

Related Resources

Marketing approval filed with FDA for Ariva-BDL as first modified risk tobacco product

February 22, 2010

Star Scientific announced that it has filed an application with the FDA for approval to market Ariva-BDL as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009.

FDA warns against use of electronic cigarettes

July 23, 2009

The FDA has notified healthcare professionals and patients that a laboratory analysis of electronic cigarette cartridge samples has found that they contain carcinogens (eg, nitrosamines) and diethylene glycol, a toxic chemical found in antifreeze.

Generic fruit and cinnamon flavored nicotine gum approved

July 08, 2009

The FDA has approved Watson's over-the-counter nicotine polacrilex gum in coated fruit and cinnamon flavors, the generic equivalent of GlaxoSmithKline Consumer Healthcare's smoking cessation aid, Nicorette Fruit Chill and Cinnamon Surge Coated gums.

Additional warnings for varenicline and bupropion

July 01, 2009

The FDA has notified healthcare professionals and patients that it has required manufacturers of varenicline (Chantix, from Pfizer) and bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL, and Zyban, from GlaxoSmithKline) to add new Boxed Warnings to the product labeling and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms.

Additional warnings for Chantix

January 18, 2008

The labeling for Chantix (varenicline tartrate, from Pfizer) has been updated with a warning to observe patients for serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior.